MedTrace Logo

A Direct Comparative Study of Tau Tracer in Patients With Alzheimer's Disease

NCT05326009 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-04-13

No results posted yet for this study

Summary

In this study, a total of 60 AD patients with Aβ deposition will beenrolled.Qualified subjects will complete PET imaging scan of Tau imaging agent inXuanwuHospital, and each subject will receive three of the following five imaging agents: PI-2620, APN1607, AV1451, RO948 or GTP1.The imaging time interval between the two tracers should be at least 4 days but less than 4 weeks. All PET scans of each subject were completed within 3 months.To compare the different Tau tracers' binding ability (SUVR or Tau distribution change) of the same subject in AD population. Obtain the safety data of each tracer after injection.

Conditions

  • Alzheimer Disease

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • Life Molecular Imaging SA

    collaborator INDUSTRY

  • APRINOIA Therapeutics

    collaborator INDUSTRY

  • XINGIMAGING LLC

    collaborator UNKNOWN

  • Hangzhou G-Bio Biotechnology Co., Ltd

    collaborator UNKNOWN

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Biao Chen, Doctor · Xuanwu Hospital, Beijing

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-20
Primary Completion
2023-01-31
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05326009 on ClinicalTrials.gov